Nuntius Therapeutics

Nuntius Therapeutics develops transformative mRNA therapies using proprietary cell-specific delivery nanocarriers, machine learning, and nucleic acid engineering. Their focus is on targeting cancer, lung diseases, and neurodegenerative diseases with non-immunogenic, programmable delivery systems.

The company develops programmable, scalable nanocarriers that target tissues and cell types beyond the liver. They use machine learning models to predict carrier quality and performance from a large library of carriers, and engineer mRNA payloads to achieve superior protein expression. Their approach combines delivery technology, ML-driven design, and nucleic acid engineering to create mRNA therapies for specific diseases.

Who it’s for: Biopharma companies and researchers developing mRNA therapies; oncology, pulmonary, and neurodegenerative disease developers; partners seeking cell-specific delivery platforms.

Partnerships and collaborations (Taiho Pharmaceutical), media coverage, stealth exit and press releases indicating active fundraising/traction